YOCHANRA Trademark

Trademark Overview


On Monday, May 9, 2022, a trademark application was filed for YOCHANRA with the United States Patent and Trademark Office. The USPTO has given the YOCHANRA trademark a serial number of 97402108. The federal status of this trademark filing is REGISTERED as of Tuesday, May 28, 2024. This trademark is owned by TransThera Sciences (Nanjing), Inc.. The YOCHANRA trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; drugs for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and di...
yochanra

General Information


Serial Number97402108
Word MarkYOCHANRA
Filing DateMonday, May 9, 2022
Status700 - REGISTERED
Status DateTuesday, May 28, 2024
Registration Number7394944
Registration DateTuesday, May 28, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements


Goods and ServicesMedicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; drugs for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemico-pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biological preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; bulk medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biochemical medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines in the nature of tablets for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders in the nature of capsule; injectable medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, May 16, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTransThera Sciences (Nanjing), Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNanjing, Jiangsu 210032
CN

Party NameTransThera Sciences (Nanjing), Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNanjing, Jiangsu 210032
CN

Party NameTransThera Sciences (Nanjing), Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNanjing, Jiangsu 210032
CN

Trademark Events


Event DateEvent Description
Thursday, May 12, 2022NEW APPLICATION ENTERED
Monday, May 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, February 25, 2023ASSIGNED TO EXAMINER
Friday, March 3, 2023NON-FINAL ACTION WRITTEN
Friday, March 3, 2023NON-FINAL ACTION E-MAILED
Friday, March 3, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 14, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 14, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, April 15, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 3, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 23, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 23, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 12, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Tuesday, September 12, 2023WITHDRAWAL OF ATTORNEY GRANTED
Thursday, November 9, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, November 9, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, November 9, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, November 9, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, November 9, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 10, 2024TEAS PETITION TO AMEND BASIS RECEIVED
Thursday, January 18, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 18, 2024SOU EXTENSION 1 FILED
Thursday, January 18, 2024SOU EXTENSION 1 GRANTED
Saturday, January 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 6, 2024ASSIGNED TO PETITION STAFF
Wednesday, February 7, 2024PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Wednesday, February 7, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, February 8, 2024NOTICE OF ALLOWANCE CANCELLED
Thursday, February 8, 2024CASE RETURNED TO EXAMINATION
Wednesday, February 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 28, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, May 28, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED